Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Part of paid clinical trials in Palo Alto, California.

Sponsor
Bolt Biotherapeutics, Inc.
Study ID
NCT06052852
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BDC-3042 — DRUG
    Dectin-2 agonist antibody
  • Cemiplimab — DRUG
    Drug which blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells

Study Details

A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies

Key Dates

Start date
Oct 11, 2023
Status verified
Nov 2025
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
17 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Single agent BDC-3042
    Escalating doses followed by expansion targeting advanced malignancies
  • Experimental: Combination BDC-3042 plus cemiplimab
    Escalating doses followed by expansion targeting advanced malignancies

Primary Outcome Measure

Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 [ Time Frame: 2 years ]

Locations (6)

FacilityCityStateZIPSite coordinators
Stanford Cancer CenterPalo AltoCalifornia94304-
Dana-Farber Cancer InstituteBostonMassachusetts02215-
NEXT OncologyAustinTexas78758-
MD Anderson Cancer CenterHoustonTexas77030-
NEXT OncologySan AntonioTexas78229-
NEXT VirginiaFairfaxVirginia22031-

Find similar trials in Palo Alto, CA

By condition
Colorectal cancerHead and neck cancerMelanomaLung cancerOvarian cancerBreast cancer
By specialty
OncologyGI oncologyENTSkin cancerDermatologyLung oncologyLung diseaseGynecologic oncologyWomen's healthBreast oncology
By research site
Stanford Cancer Center· Palo Alto, CADana-Farber Cancer Institute· Boston, MANEXT Oncology· Austin, TXMD Anderson Cancer Center· Houston, TXNEXT Oncology· San Antonio, TXNEXT Virginia· Fairfax, VA

Related Studies